Age Related Macular Degeneration and Diabetic Retinopathy Drugs Market

Age related macular degeneration (AMD) is a medical condition that results in loss of vision in the central visual field, owing to damage to the retina. This is usually an age-related disorder, which affects adults with the age 50 and above. Diabetic retinopathy is an ophthalmic disorder, in which blindness occurrs due to complications in diabetes.
Age Related Macular Degeneration and Diabetic Retinopathy Drugs Market contains market size and forecasts of Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs in global, including the following market information:
Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Sales, 2017-2022, 2023-2028, (K MT)
Global top five Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs companies in 2021 (%)
The global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Macular Degeneration Drugs Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs include Novartis, Bayer Healthcare, Roche, Neurotech Pharmaceuticals, Regeneron Pharmaceuticals and Allergan, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K MT)
Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Segment Percentages, by Type, 2021 (%)
Macular Degeneration Drugs
Diabetic Retinopathy Drugs
Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K MT)
Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Segment Percentages, by Application, 2021 (%)
50-60 Years Old
60-70 Years Old
Others
Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K MT)
Global Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs revenues share in global market, 2021 (%)
Key companies Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs sales in global market, 2017-2022 (Estimated), (K MT)
Key companies Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novartis
Bayer Healthcare
Roche
Neurotech Pharmaceuticals
Regeneron Pharmaceuticals
Allergan